Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Collen

Showing results (441-450 of 715) with videos related to

Pageof 72
Sort By:
Thrombosis Research|March 1, 1984
Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditionsI Juhan-Vague, B Moerman, F De Cock, et al.
Thrombosis and Haemostasis|January 1, 1994
Expression and characterization of clustered charge-to-alanine mutants of low M(r) single-chain urokinase-type plasminogen activatorS Ueshima, P Holvoet, H R Lijnen, et al.
Thrombosis and Haemostasis|August 20, 1986
Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitroD Collen, F De Cock, E Demarsin, et al.
Circulation|September 1, 1991
Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activatorsD Collen, H R Lu, H R Lijnen, et al.
Thrombosis Research|October 15, 1985
Aspirin, indomethacin and dazoxiben do not affect the fibrinolytic activation induced by venous occlusionH Bounameaux, P Gresele, M Hanss, et al.
European Journal of Biochemistry|August 15, 1988
Purification and characterization of natural and recombinant human plasminogen activator inhibitor-1 (PAI-1)M C Alessi, P J Declerck, M De Mol, et al.
Acta Clinica Belgica|January 1, 1992
A randomized placebo controlled trial on the effects of simvastatin, a HMG-CoA reductase inhibitor, on blood lipids and fibrinolytic parametersH Jacobs, F Van de Werf, E Lesaffre, et al.
European Heart Journal|August 1, 1987
Treatment of prosthetic tricuspid valve thrombosis with recombinant tissue-type plasminogen activatorP Cambier, P Mombaerts, H De Geest, et al.
Thrombosis and Haemostasis|April 25, 1989
Binding properties of monoclonal antibodies against human fragment D-dimer of cross-linked fibrin to human plasma clots in an in vivo model in rabbitsP Holvoet, J M Stassen, Y Hashimoto, et al.
Thrombosis and Haemostasis|October 30, 1985
Plasminogen activator inhibitor (PA-inhibitor) activity in the blood of patients with deep vein thrombosisJ A Paramo, A de Boer, M Colucci, et al.
Pageof 72

Showing results (441-450 of 715) with videos related to

Sort By:
Pageof 72
Thrombosis Research|March 1, 1984
Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditionsI Juhan-Vague, B Moerman, F De Cock, et al.
Thrombosis and Haemostasis|January 1, 1994
Expression and characterization of clustered charge-to-alanine mutants of low M(r) single-chain urokinase-type plasminogen activatorS Ueshima, P Holvoet, H R Lijnen, et al.
Thrombosis and Haemostasis|August 20, 1986
Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitroD Collen, F De Cock, E Demarsin, et al.
Circulation|September 1, 1991
Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activatorsD Collen, H R Lu, H R Lijnen, et al.
Thrombosis Research|October 15, 1985
Aspirin, indomethacin and dazoxiben do not affect the fibrinolytic activation induced by venous occlusionH Bounameaux, P Gresele, M Hanss, et al.
European Journal of Biochemistry|August 15, 1988
Purification and characterization of natural and recombinant human plasminogen activator inhibitor-1 (PAI-1)M C Alessi, P J Declerck, M De Mol, et al.
Acta Clinica Belgica|January 1, 1992
A randomized placebo controlled trial on the effects of simvastatin, a HMG-CoA reductase inhibitor, on blood lipids and fibrinolytic parametersH Jacobs, F Van de Werf, E Lesaffre, et al.
European Heart Journal|August 1, 1987
Treatment of prosthetic tricuspid valve thrombosis with recombinant tissue-type plasminogen activatorP Cambier, P Mombaerts, H De Geest, et al.
Thrombosis and Haemostasis|April 25, 1989
Binding properties of monoclonal antibodies against human fragment D-dimer of cross-linked fibrin to human plasma clots in an in vivo model in rabbitsP Holvoet, J M Stassen, Y Hashimoto, et al.
Thrombosis and Haemostasis|October 30, 1985
Plasminogen activator inhibitor (PA-inhibitor) activity in the blood of patients with deep vein thrombosisJ A Paramo, A de Boer, M Colucci, et al.
Pageof 72